20% off purchase of 3 or more products* | Learn More >>

Abc Family Research Area

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Monkey, Mouse

Application Methods: Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: ABCC4 is a member of the ATP-binding Cassette (ABC) transporter family. ABC proteins transport various molecules across cellular membranes by utilizing the energy generated from ATP hydrolysis. There are seven subfamilies of ABC proteins: ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White (1). ABCC4 belongs to the MRP subfamily, which is involved in multi-drug resistance, hence it is also named MRP4. ABCC4 is widely expressed in tissues including prostate, kidney proximal tubules, astrocytes and capillary endothelial cells of the brain, platelets, and many cancer cell lines (2-4). ABCC4 mediates efflux transport of a wide variety of endogenous and xenobiotic organic anionic compounds (5). The diversity of substrates determines the biological functions of ABCC4. It regulates cAMP levels in human leukemia cells, thereby controlling the proliferation and differentiation of leukemia cells (6). ABCC4 also enables COX deficient pancreatic cancer cells to obtain exogenous prostaglandins (7). Research studies have shown that ABCC4 expression is elevated in drug resistant cancer cells, which makes it a potential target for cancer therapy (8,9). ABCC4 localizes to both plasma membrane and intracellular membranous structures (10). Investigators have also implicated ABCC4 in the pathogenesis of Kawasaki disease, a childhood genetic disorder characterized by vasculitis (11).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: ABCC4 is a member of the ATP-binding Cassette (ABC) transporter family. ABC proteins transport various molecules across cellular membranes by utilizing the energy generated from ATP hydrolysis. There are seven subfamilies of ABC proteins: ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, and White (1). ABCC4 belongs to the MRP subfamily, which is involved in multi-drug resistance, hence it is also named MRP4. ABCC4 is widely expressed in tissues including prostate, kidney proximal tubules, astrocytes and capillary endothelial cells of the brain, platelets, and many cancer cell lines (2-4). ABCC4 mediates efflux transport of a wide variety of endogenous and xenobiotic organic anionic compounds (5). The diversity of substrates determines the biological functions of ABCC4. It regulates cAMP levels in human leukemia cells, thereby controlling the proliferation and differentiation of leukemia cells (6). ABCC4 also enables COX deficient pancreatic cancer cells to obtain exogenous prostaglandins (7). Research studies have shown that ABCC4 expression is elevated in drug resistant cancer cells, which makes it a potential target for cancer therapy (8,9). ABCC4 localizes to both plasma membrane and intracellular membranous structures (10). Investigators have also implicated ABCC4 in the pathogenesis of Kawasaki disease, a childhood genetic disorder characterized by vasculitis (11).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Western Blotting

Background: ABCG2 (BCRP1/ABCP/MXR) is a member of the ATP-binding cassette transporter family that functions as ATP-dependent transporters for a wide variety of chemical compounds and are associated with drug-resistance in cancer cells (1-6). ABCG2 is a heavily glycosylated transmembrane protein with six transmembrane spanning regions consistent with it functioning as a half-transporter. The ABC family can exist as either full-length transporters or as half-transporters that form functional transporters through homo- or heterodimerization. High expression of ABCG2 was found in placenta as well as cell lines selected for resistance to a number of chemotherapeutic drugs, including mitoxantrone, doxorubicin, topotecan and flavopiridol. In rodents, the highest expression of ABCG2 was found in kidney (8). ABCG2 expression has also been observed in stem cell populations, particularly in hematopoietic and neuronal stem cells and is downregulated with differentiation (9-12).

$122
20 µl
$293
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: ABCG2 (BCRP1/ABCP/MXR) is a member of the ATP-binding cassette transporter family that functions as ATP-dependent transporters for a wide variety of chemical compounds and are associated with drug-resistance in cancer cells (1-6). ABCG2 is a heavily glycosylated transmembrane protein with six transmembrane spanning regions consistent with it functioning as a half-transporter. The ABC family can exist as either full-length transporters or as half-transporters that form functional transporters through homo- or heterodimerization. High expression of ABCG2 was found in placenta as well as cell lines selected for resistance to a number of chemotherapeutic drugs, including mitoxantrone, doxorubicin, topotecan and flavopiridol. In rodents, the highest expression of ABCG2 was found in kidney (8). ABCG2 expression has also been observed in stem cell populations, particularly in hematopoietic and neuronal stem cells and is downregulated with differentiation (9-12).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: CFTR (ABC35, ABCC7, CBAVD, CF, dj760C5.1, MRP7, TNR-CFTR) is a member of the ATP-binding cassette (ABC) transporter superfamily. Mutations in ABC genes have been linked to many diseases. CFTR is a plasma membrane cyclic AMP activated chloride channel that is expressed in the epithelial cells of the lung and several other organs (1,2). It mediates the secretion of Cl- and also regulates several channels including the epithelial sodium channel (ENaC), K+ channels , ATP release mechanisms, anion exchangers, sodium bicarbonate transporters and aquaporin water channels (3,4,5,6,7,8 9,10). Mutations in the CFTR gene cause cystic fibrosis, a disease that is characterized by exocrine pancreatic insufficiency, increase in sweat gland NaCl, male infertility and airway disease (1,2,11). Intracellular trafficking regulates the number of CFTR molecules at the cell surface, which in part regulates Cl- secretion. Deletion of phenylalanine 508 (deltaF508) is the most common mutation in CF patients. This mutation results in retention in the ER, where ER quality control mechanisms target the deltaF508 mutant to the proteosome for degradation (12-14). Therefore, disruption of CFTR trafficking leads to disregulation of Cl- secretion at the plasma membrane of epithelial cells.

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: Multi-drug resistance protein 2 (MRP2), also known as cMRP, cMOAT, and ABCC2, is an ATP binding cassette (ABC) transporter and part of the multi-drug resistance (MRP) family (1,2). The MRP proteins are membrane proteins that function as organic anion pumps involved in the cellular removal of cancer drugs (2). MRP2 is associated with resistance to a number of cancer drugs, such as cisplatin, etoposide, doxorubicin, and methotrexate (3-5). MRP2 is predominately expressed on the apical membranes in the liver (6-9) and kidney proximal tubules (10). It is responsible for the ATP-dependent secretion of bilirubin glucuronides and other organic anions from hepatocytes into the bile, a process important for the excretion of endogenous and xenobiotic substances. Loss of MRP2 activity is the cause of Dubin-Johnson syndrome, an autosomal recessive disorder characterized by defects in the secretion of anionic conjugates and the presence of melanin like pigments in hepatocytes (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: The multidrug resistance-associated protein 6 (MRP6, ABCC6) is a member of ATP-binding cassette (ABC) family transporters that move drugs and hydrophobic compounds across cell membranes. The MRP6 protein is expressed mainly in liver and kidney, and in other tissues to a lesser extent (1). Identified MRP6 substrates include the glutathione conjugate of N-ethylmaleimide (NEM-GS) and leukotriene C4 (LTC4), with more tentative MRP6 substrates under investigation (2,3). Research studies show that increased MRP6 expression correlates with induced cholesterol biosynthesis, which suggests that MRP6 may be involved in lipid and cholesterol homeostasis (4). A small isoform of MRP6 is up-regulated in HBV infected hepatocytes and protects the cells from apoptosis mediated by caspase 3 and caspase 8 (5,6). Mutations in the corresponding ABCC6 gene cause pseudoxanthoma elasticum (PXE), an autosomal recessive disorder that is characterized by the accumulation of mineralized and fragmented elastic fibers in the skin, eyes, and arteries (7,8). Mutations in ABCC6 also result in generalized arterial calcification of infancy, an ectopic calcification disease that lies along a spectrum of similar disorders with PXE (9).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: Multi-drug resistance protein 2 (MRP2), also known as cMRP, cMOAT, and ABCC2, is an ATP binding cassette (ABC) transporter and part of the multi-drug resistance (MRP) family (1,2). The MRP proteins are membrane proteins that function as organic anion pumps involved in the cellular removal of cancer drugs (2). MRP2 is associated with resistance to a number of cancer drugs, such as cisplatin, etoposide, doxorubicin, and methotrexate (3-5). MRP2 is predominately expressed on the apical membranes in the liver (6-9) and kidney proximal tubules (10). It is responsible for the ATP-dependent secretion of bilirubin glucuronides and other organic anions from hepatocytes into the bile, a process important for the excretion of endogenous and xenobiotic substances. Loss of MRP2 activity is the cause of Dubin-Johnson syndrome, an autosomal recessive disorder characterized by defects in the secretion of anionic conjugates and the presence of melanin like pigments in hepatocytes (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunohistochemistry (Paraffin), Western Blotting

Background: MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: MRP3/ABCC3 belongs to the super family of ATP-binding cassette (ABC) transporters. It is a member of the MRP subfamily that is expressed in various organs including liver, gallbladder, small intestine, colon, kidney, and adrenal gland (1-3). MRP3 is involved in multi-drug resistance (1). It facilitates the efflux of organic anions including monoanionic bile acid and anti-cancer reagents such as etoposide and paclitaxel from liver and small intestine into blood (4-7). Expression of MRP3 is increased in the cholestatic human and rat liver, suggesting its role in cholehepatic and enterohepatic bile circulation and in protecting liver from toxic bile salts (2,8). MRP3 expression is also upregulated in people with Dubin-Johnson Syndrome (DJS) who lack functional MRP2 in the liver, which implicates the compensatory role of MRP3 in the absence of functional MRP2 (4).Elevated expression of MRP3 has been detected in various cancer types such as hepatocellular carcinomas, primary ovarian cancer, and adult acute lymphoblastic leukemia (ALL) (9-11). Overexpression of MRP3 was reported to be a prognostic factor in ALL and adult acute myeloid leukemia (AML) (11,12).

$260
100 µl
APPLICATIONS
REACTIVITY
Human, Mouse, Rat

Application Methods: Immunoprecipitation, Western Blotting

Background: MRP3/ABCC3 belongs to the super family of ATP-binding cassette (ABC) transporters. It is a member of the MRP subfamily that is expressed in various organs including liver, gallbladder, small intestine, colon, kidney, and adrenal gland (1-3). MRP3 is involved in multi-drug resistance (1). It facilitates the efflux of organic anions including monoanionic bile acid and anti-cancer reagents such as etoposide and paclitaxel from liver and small intestine into blood (4-7). Expression of MRP3 is increased in the cholestatic human and rat liver, suggesting its role in cholehepatic and enterohepatic bile circulation and in protecting liver from toxic bile salts (2,8). MRP3 expression is also upregulated in people with Dubin-Johnson Syndrome (DJS) who lack functional MRP2 in the liver, which implicates the compensatory role of MRP3 in the absence of functional MRP2 (4).Elevated expression of MRP3 has been detected in various cancer types such as hepatocellular carcinomas, primary ovarian cancer, and adult acute lymphoblastic leukemia (ALL) (9-11). Overexpression of MRP3 was reported to be a prognostic factor in ALL and adult acute myeloid leukemia (AML) (11,12).

$269
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blotting

Background: Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of ATP-binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion transporter. It has a broad range of substrates, including antineoplastic or therapeutic agents and the glutathione (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates such as folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins (2,3).Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 has been found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate cancer (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of therapeutic agents from cancer cells and confers drug resistance in those patients. Research studies also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast cancer and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity of chemotherapeutic agents in those patients (6-10).

$262
3 nmol
300 µl
SignalSilence® MDR1/ABCB1 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit MDR1/ABCB1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
REACTIVITY
Human

Background: MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

$262
3 nmol
300 µl
SignalSilence® MDR1/ABCB1 siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit MDR1/ABCB1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
REACTIVITY
Human

Background: MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: MDR1/ABCB1 belongs to the Mdr/Tap subfamily of the ATP-binding cassette transporter superfamily (1). Multidrug resistance 1 (MDR1) serves as an efflux pump for xenobiotic compounds with broad substrate specificity. MDR1 substrates include therapeutic agents such as actinomycin D, etoposide, imatinib, and doxorubicin, as well as endogenous molecules including β-amyloids, steroid hormones, lipids, phospholipids, cholesterol, and cytokines (2). Research studies have shown that MDR1 reduces drug accumulation in cancer cells, allowing the development of drug resistance (3-5). On the other hand, MDR1 expressed in the plasma membrane of cells in the blood-brain, blood-cerebral spinal fluid, or blood-placenta barriers restricts the permeability of drugs into these organs from the apical or serosal side (6,7). MDR1 is also expressed in normal tissues with excretory function such as small intestine, liver, and kidney (7). Intracellular MDR1 has been detected in the ER, vesicles, and nuclear envelope, and has been associated with cell trafficking machinery (8). Other reported functions of MDR1 include viral resistance, cytokine trafficking (9,10), and lipid homeostasis in the peripheral and central nervous system (11-13).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunofluorescence (Immunocytochemistry), Immunoprecipitation, Western Blotting

Background: Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the MRP subfamily of ATP-binding cassette (ABC) transporters (1). MRP1/ABCC1 protein functions as an organic anion transporter. It has a broad range of substrates, including antineoplastic or therapeutic agents and the glutathione (GSH) conjugates of these compounds. MRP1/ABCC1 also transports physiological substrates such as folates, GSH and GSH disulfide (GSSG) conjugates of steroids, leukotrienes, and prostaglandins (2,3).Although MRP1/ABCC1 is generally expressed in normal tissue, upregulation of MRP1/ABCC1 has been found in a variety of solid tumors, including small cell lung cancer, breast cancer, and prostate cancer (1,4,5). Research studies show that overexpression of MRP1/ABCC1 facilitates the elimination of therapeutic agents from cancer cells and confers drug resistance in those patients. Research studies also show that elevated expression of MRP1/ABCC1 is a negative prognostic marker for breast cancer and small cell lung cancer, as the level of MRP1/ABCC1 is predictive of the response and toxicity of chemotherapeutic agents in those patients (6-10).

$260
100 µl
APPLICATIONS
REACTIVITY
Human

Application Methods: Immunoprecipitation, Western Blotting

Background: ApoAI (Apolipoprotein A1) is a major component of high density lipoprotein (HDL, the “good cholesterol”) in plasma. It is produced in the liver and small intestine. ApoA1 is a cofactor for lecithin cholesterolacyltransferase (LCAT) that is responsible for the formation of plasma cholesteryl esters and promotes cholesterol efflux from tissues to the liver for excretion. Defects in ApoA1 are associated with high density lipoprotein deficiency (HDLD) and systemic non-neuropathic amyloidosis (1-3).